Evaluation of 68Ga-DOTATATE uptake at the pituitary region and the biochemical response to somatostatin analogs in acromegaly

Abstract

Purpose

Acromegaly is associated with many comorbidities and increased mortality. The first-line treatment is transsphenoidal surgery. However, many patients also need adjuvant drug treatment after surgery. Somatostatin analog (SSA), which suppresses GH secretion by somatotrophs by binding to the SSTR2 receptor, is the first choice. Nevertheless, 50% of patients are partially or totally resistant to SSA, so predictive factors of response are helpful to individualize drug treatment. 68GaDOTATATE PET/CT has emerged as the gold-standard method in the diagnosis and follow-up of gastroenteropancreatic neuroendocrine tumors, which also express SSTR. Our objective was to evaluate whether 68Ga-DOTATATE uptake (SUV max) at the pituitary region of patients on SSA therapy would be useful as a drug response predictor without the need of tumoral tissue.

Methods

Fifteen acromegalics patients on SSA treatment for at least 6 months were underwent to 68Ga-DOTATATE PET/CT at the nuclear medicine service. There was an SSA complete response group (n = 5), defined as GH < 1 µg/L and IFG-1 in the normal range for gender and age, and a group that did not meet these criteria (n = 10).

Results

As a result, we did not find out a significantly higher SUV max in the complete response group (p = 0.0576) to SSA. However, we found a significant inverse relationship between postoperative GH values and the SUVmax at the sella turcica (p = 0.0188), probably reflecting tumor SSTR2 expression.

Conclusion

Thus, after this initial evaluation, 68GaDOTATATE PET/CT should be better studied to assess its usefulness in the follow-up of acromegalic patients.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951

    CAS  Article  Google Scholar 

  2. 2.

    Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS (2018) Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 179(1):59–71

    CAS  Article  Google Scholar 

  3. 3.

    Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A Consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552–561

    Article  Google Scholar 

  4. 4.

    Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R (2019) Acromegaly. Nat Rev Dis Primers 5(1):20

    Article  Google Scholar 

  5. 5.

    Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100(1):122–131

    CAS  Article  Google Scholar 

  6. 6.

    Paragliola RM, Corsello SM, Salvatori R (2017) Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary 20(1):109–115

    CAS  Article  Google Scholar 

  7. 7.

    Tortora F, Negro A, Grasso LFS, Colao A, Pivonello R, Splendiani A, Brunese L, Caranci F (2019) Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas. Gland Surg 8(Suppl 3):S150–S158

    Article  Google Scholar 

  8. 8.

    Potorac I, Beckers A, Bonneville JF (2017) T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. Pituitary 20(1):116–120

    CAS  Article  Google Scholar 

  9. 9.

    Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Centeno RG, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJ, Delemer B, Petit JM, Schöfl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23(11):871881

    Article  Google Scholar 

  10. 10.

    Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490–498

    CAS  Article  Google Scholar 

  11. 11.

    Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC (2016) Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med 57(5):708–714

    CAS  Article  Google Scholar 

  12. 12.

    Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112(11):2447–2455

    Article  Google Scholar 

  13. 13.

    Conover WJ (1999) Practical nonparametric statistics, 3a edn. John Wiley & Sons Inc., Nova Iorque

    Google Scholar 

  14. 14.

    Fleiss JL (1981) Statistical methods for rates and proportions, 2a edn. John Wiley & Sons Inc., Nova Iorque

    Google Scholar 

  15. 15.

    Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D (2017) Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 20(1):100–108

    CAS  Article  Google Scholar 

  16. 16.

    Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, Subramaniam RM (2018) Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET/CT. Am J Roentgenol 211(2):267–277

    Article  Google Scholar 

  17. 17.

    Cremonini N, Furno A, Sforza A, Chiarini V, Graziano E, Zampa G, Turba E (1995) 111Inoctreotide scintigraphy in endocrine tumors. Preliminary data. Q J Nucl Med 39(4 Suppl 1):116–120

    CAS  PubMed  Google Scholar 

  18. 18.

    Tirosh A, Kebebew E (2018) The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol 14(2):111–122

    CAS  Article  Google Scholar 

  19. 19.

    Ito T, Jensen RT (2017) Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes 24(1):15–24

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81(6):2356–2362

    CAS  PubMed  Google Scholar 

  21. 21.

    Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, Attanasio R, Milella M, Banfi G, Possa M (1998) Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors. J Endocrinol Invest 21(8):5129

    Article  Google Scholar 

  22. 22.

    Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ (1997) Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 136(4):369–376

    Article  Google Scholar 

  23. 23.

    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ (1994) Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79(5):1416–1423

    PubMed  Google Scholar 

  24. 24.

    Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N (1997) Indiumpentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J Endocrinol Invest 20(7):424–428

    CAS  Article  Google Scholar 

  25. 25.

    Coura-Filho GB, Hoff AAFO, Duarte PS, Buchpiguel CA, Josefsson A, Hobbs RF, Sgouros G, Sapienza MT (2019) 68Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours. Nucl Med Commun 40(9):920–926

    CAS  Article  Google Scholar 

  26. 26.

    Iglesias P, Cardona J, Díez JJ (2019) The pituitary in nuclear medicine imaging. Eur J Intern Med 68:6–12

    CAS  Article  Google Scholar 

  27. 27.

    Waligórska-Stachura J, Gut P, Sawicka-Gutaj N, Liebert W, Gryczyńska M, Baszko-Błaszyk D, Blanco-Gangoo AR, Ruchała M (2016) Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report. J Neurosurg 125(2):346–349

    Article  Google Scholar 

  28. 28.

    d’Amico A, Stąpór-Fudzińska M, Tarnawski R (2014) CyberKnife radiosurgery planning of a secreting pituitary adenoma performed with 68Ga DOTATATE PET and MRI. Clin Nucl Med 39(12):1043–1044

    Article  Google Scholar 

  29. 29.

    Wang H, Hou B, Lu L, Feng M, Zang J, Yao S, Feng F, Wang R, Li F, Zhu Z (2018) PET/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study. J Nucl Med 59(3):523–528

    CAS  Article  Google Scholar 

  30. 30.

    Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189–3202

    CAS  Article  Google Scholar 

  31. 31.

    Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A (2010) Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68GaDOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37(10):2004–2010

    Article  Google Scholar 

  32. 32.

    Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG (2002) Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 146(3):295–302

    CAS  Article  Google Scholar 

  33. 33.

    Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocr Metab 98(11):E1730–E1739

    CAS  Article  Google Scholar 

  34. 34.

    Koulouri O, Kandasamy N, Hoole AC, Gillett D, Heard S, Powlson AS, O’Donovan DG, Annamalai AK, Simpson HL, Akker SA, Aylwin SJ, Brooke A, Buch H, Levy MJ, Martin N, Morris D, Parkinson C, Tysome JR, Santarius T, Donnelly N, Buscombe J, Boros I, Smith R, Aigbirhio F, Antoun NM, Burnet NG, Cheow H, Mannion RJ, Pickard JD, Gurnell M (2016) Successful treatment of residual pituitary adenoma in persistent acromegaly following localization by 11C-methionine PET co-registered with MRI. Eur J Endocrinol 175(5):485–498

    CAS  Article  Google Scholar 

Download references

Funding

We did not receive any funding for this survey. 68Ga-DOTATATE doses were donated by the Institute of Energy and Nuclear Research (IPEN).

Author information

Affiliations

Authors

Contributions

All the authors participated sufficiently in the work to take public responsibility for its content.

Corresponding authors

Correspondence to K. B. Daniel or H. M. Garmes.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval

The Ethics Committee on Research approved the study in Human Beings under number 70882317.4.0000.5404. Written informed consents were obtained from all participants.

Informed consent

The participating subjects provided the written informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Daniel, K.B., de Oliveira Santos, A., de Andrade, R.A. et al. Evaluation of 68Ga-DOTATATE uptake at the pituitary region and the biochemical response to somatostatin analogs in acromegaly. J Endocrinol Invest (2021). https://doi.org/10.1007/s40618-021-01523-6

Download citation

Keywords

  • Acromegaly
  • 68Ga-DOTATATE
  • Somatostatin analogs
  • SSTR2